RET, ret proto-oncogene, 5979

N. diseases: 607; N. variants: 162
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Differentiated Thyroid Gland Carcinoma
0.100 Biomarker disease BEFREE The clinicopathologic characteristics of CCV-PTC and the paraneoplastic syndromes in follicular cell differentiated thyroid carcinoma were further summarized using literature review. 29446856 2018
Differentiated Thyroid Gland Carcinoma
0.100 GeneticVariation disease BEFREE Associations between RET tagSNPs and their haplotypes and susceptibility, clinical severity, and thyroid function in patients with differentiated thyroid cancer. 29131865 2017
Differentiated Thyroid Gland Carcinoma
0.100 AlteredExpression disease BEFREE CR = complete response; DM = distant metastases; DTC = differentiated thyroid cancer; ETE = extra-thyroidal extension; M0 = detected during follow-up; M1 = detected at diagnosis; MSKCC = Memorial Sloan Kettering Cancer Center; NED = no evidence of disease; OS = overall survival; PFS = progression free survival; PTC = papillary thyroid cancer; RAI = radioactive iodine; Tg = thyroglobulin. 28704099 2017
Differentiated Thyroid Gland Carcinoma
0.100 GeneticVariation disease BEFREE The prevalence of various somatic mutations in differentiated thyroid cancer was similar in Taiwan and Western countries, with the RAS kinase mutation and tyrosine receptor kinase (TRK) and rearranged during transfection (RET) proto-oncogenes being detected in lower frequencies and the B-type RAF kinase (BRAF) mutation accounting for the majority of cases. 25455162 2015
Differentiated Thyroid Gland Carcinoma
0.100 GeneticVariation disease BEFREE Our results confirm that the FOXE1 rs965513 SNP confers an increased risk for DTC in the German population, particularly allele "A" and the genotypes "AA" and "AG" for PTC. 24325646 2014
Differentiated Thyroid Gland Carcinoma
0.100 GeneticVariation disease BEFREE Several diagnostic and prognostic molecular markers such as BRAF and RAS point mutations; RET/PTC and PAX8/PPARγ gene rearrangements; MAPK, PI3K, p53, Wnt-beta catenin, HIF1α and NF-kappaB signaling pathways; microRNA profiles and aberrant methylation have been demonstrated in more than 70% of DTC. 24405857 2014
Differentiated Thyroid Gland Carcinoma
0.100 GeneticVariation disease BEFREE We have developed a home-brew tetracolor break-apart probe able to simultaneously identify the 2 most common genetic alterations in differentiated thyroid carcinoma: RET/PTC variants in papillary thyroid carcinoma and PAX8/PPARg fusion and variants in follicular thyroid carcinoma. 24510380 2014
Differentiated Thyroid Gland Carcinoma
0.100 GeneticVariation disease BEFREE The aim of this case-control study was to determine the effect of four well known RET single nucleotide polymorphisms (SNPs) on the risk for differentiated thyroid carcinoma. 25330015 2014
Differentiated Thyroid Gland Carcinoma
0.100 GeneticVariation disease BEFREE Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. 23828865 2013
Differentiated Thyroid Gland Carcinoma
0.100 GeneticVariation disease BEFREE German patients (n=253) with DTC (papillary thyroid carcinoma [PTC] and follicular thyroid carcinoma [FTC]) and HC (n=302) were genotyped for polymorphisms within the vitamin D metabolizing enzymes such as 25-hydroxylase (CYP2R1[rs12794714, rs10741657]), 25-hydroxyvitamin D-1α-hydroxylase (CYP27B1[rs10877012, rs4646536]), and 25-hydroxyvitamin D 24-hydrolase (CYP24A1[rs927650, rs2248137, rs2296241]). 22690899 2012
Differentiated Thyroid Gland Carcinoma
0.100 Biomarker disease BEFREE Genetic alterations in the mitogen-activated protein kinase pathway, including mutations of BRAF, RAS, and RET genes, have been implicated in the development of differentiated thyroid carcinoma arising in the thyroid gland. 19898969 2010
Differentiated Thyroid Gland Carcinoma
0.100 GeneticVariation disease BEFREE The genotype distributions were similar between DTC cases (n = 101) and controls (n = 174) except for RET 7 and RET 14 (P = .003 and P = .047, respectively) and between BTD cases (n = 62) and controls except for RET 14 (borderline; P = .064). 15933516 2005
Differentiated Thyroid Gland Carcinoma
0.100 Biomarker disease BEFREE In conclusion, chromosomal abnormalities are frequent in ATCs associated with FTC, but uncommon in those associated with PTC and in ATCs with no associated differentiated thyroid cancer. 12729478 2003